Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003384 · ClinicalTrials.gov registry record · NA

Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer

A NA study of Precancerous Condition and Stage 0 Cervical Cancer, sponsored by Gynecologic Oncology Group.

Completed
Registry status
NA
Development phase
684
Enrollment target
1
Study location

NCT00003384: Completed NA study of Precancerous Condition and Stage 0 Cervical Cancer, sponsored by Gynecologic Oncology Group.

NCT00003384 is a NA study of Precancerous Condition and Stage 0 Cervical Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 684 participants, above the 577-participant average among 15 other Precancerous Condition trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003384, a NA study of Precancerous Condition and Stage 0 Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
NA
Development phase
684 participants
Enrollment target
1
Study location

Study Summary

This diagnostic trial is studying the presence of a specific protein as a potential biomarker of cervical dysplasia and/or cancer. The presence of specific proteins may allow a doctor to determine whether a patient has cervical dysplasia and/or cancer.

Interventions

  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Conization
  • OTHER Cervical Papanicolaou Test

Study Locations (1)

Arizona

  • Gynecologic Oncology Group of Arizona - Phoenix

Trial Details

FieldValue
Enrollment Target 684 participants
Start Date 1998-09
Phase NA
Gynecologic Oncology Group

154 total trials

What the finished NCT00003384 record still lists

NCT00003384 is an interventional study that assigns participants to a tested intervention. The registered 684 participants enrollment target is mid-sized for trials with a published cap, above the 577-participant average among 15 other Precancerous Condition trials with a reported enrollment target (19% higher).

The record links to 2 conditions, with Precancerous Condition appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT00003384 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT00003384 about?

NCT00003384 is a clinical study titled "Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer". This diagnostic trial is studying the presence of a specific protein as a potential biomarker of cervical dysplasia and/or cancer. The presence of specific proteins may allow a doctor to determine whether a patient has cervical dysplasia and/or cancer.

What is the current status of trial NCT00003384?

This trial is currently completed. It is a NA study. The enrollment target is 684 participants. The study started on 1998-09.

What conditions does trial NCT00003384 study?

This clinical trial studies the following conditions: Precancerous Condition, Stage 0 Cervical Cancer.

What interventions are being tested in trial NCT00003384?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Conization (PROCEDURE), Cervical Papanicolaou Test (OTHER).

Who is sponsoring clinical trial NCT00003384?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003384 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Precancerous Condition

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00003384's enrollment target sits among peer trials

684 4th of 15 higher than 12 of 15 other Precancerous Condition trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Precancerous Condition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06795087 · 684 participants

    Discharge Medication Use Post-Operatively in GU Cancer Patients

  • NCT05099770 · 685 participants · Phase 3

    Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

  • NCT05880199 · 685 participants

    BSGM to Evaluate Patients With GI Symptoms

  • NCT04333537 · 686 participants · Phase 2

    Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003384, the US trial registry maintained by the National Library of Medicine. NCT00003384 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.